Zusammenfassung
Das Kapitel soll einen Überblick über die Genetik gesundheitsbezogener Fitness einschließlich körperlicher Leistungsfähigkeit und Training aufzeigen. Hierbei werden die neuesten und wichtigsten Erkenntnisse zusammengefasst und ein Ausblick in die Zukunft geben. Ein Großteil der genetischen Daten basiert auf Forschungsergebnissen aus Untersuchungen zu Volkskrankheiten wie Adipositas und Diabetes mellitus Typ 2. Zusätzlich werden die Daten aus den leistungssportassoziierten Untersuchungen zusammengefasst und gewertet. Zahlreiche autosomale mitochondriale Gene mit Assoziation zur körperlichen Leistungsfähigkeit und gesundheitsbezogenen Fitness werden diskutiert. Allerdings muss berücksichtigt werden, dass die Mehrzahl der genetischen Erkenntnisse aktuell noch auf relativ kleinen Stichproben basiert und daher differenziert zu interpretieren ist.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Osborne KA, Robichon A, Burgess E, Butland S, Shaw RA, Coulthard A, Pereira HS, Greenspan RJ, Sokolowski MB (1997) Natural behavior polymorphism due to a cGMP-dependent protein kinase of Drosophila. Science 277 (5327): 834–6
Bray MS, Hagberg JM, PÉRusse L (2009) The Human Gene Map for Performance and Health-Related Fitness Phenotypes: the 2006–2007 update. Med Sci Sports Exerc. 41: 35–73
Grobet L, Martin LJ, Poncelet D et al. (1997) A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 17: 71–74
Longmore GD (1993) Erythropoietin receptor mutations and Olympic glory [news]. Nature Genetics. 4: 108–110
Juvonen E, Ikkala E, Fyhrquist F, Ruutu T (1991) Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood. 78: 3066–3069
de la Chapelle A, Träskelin AL, Juvonen E (1993) Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA. 90
Bouchard C, Dionne FT, Simoneau JA, Boulay MR (1992) Genetics of aerobic and anaerobic performances. Exerc Sport Sci Rev. 20: 27–58
Larsen HB (2003) Kenyan Dominance in Distance Running. Comp Biochem Physiol A Mol Integr Physiol. 136: 161–170
Hamilton B, Weston A (2000) Perspectives on East African Middle and Long Distance Running. J Sci Med Sport. 3: vi–viii
Jobling MA, Hurles ME, Tyler-Smith C (2004) Human Evolutionary Genetics: origins, peoples and disease. Garland Science Publishing. 523
Entine J (2001) Taboo: Why Black Athletes Dominate Sports And Why We're Afraid To Talk About It. New York:PublicAffairs
Klissouras V (1971) Heritability of adaptive variation. J Appl Physiol. 31: 338–344
Komi P, Viitasalo J, Havu M, Thorstensson A, Sjödin B, Karlsson J (1977) Skeletal muscle fibres and muscle enzyme activities in monozygous and dizygous twins of both sexes. Acta Physiol Scand. 100: 385–392
Weber G, Kartodihardjo W, Klissouras V (1976) Growth and physical training with reference to heredity. J Appl Physiol. 40: 211–215
Kovar R (1977) Somatotypes of twins. Acta Univ Carol Gymn. 13: 49–59
Sklad M (1977) Skeletal maturation in monozygotic and dizygotic twins. J Hum Evol. 6: 145–149
Williams LRT, Gross JB (1980) Heritability of motor skill. Acta Genet Med. 29: 127–36
Orvanova E (1984) Body build, heredity and sport achievements. In Genetics of Psychomotor Traits in Man. International Society of Sport Genetics and Somatology, Warsaw. 111–123
Bouchard C, Lesage R, Lortie G (1986) Aerobic performance in brothers, dizygotic and monozygotic twins Med Sci Sports Exerc. 18: 639–646
Fagard R, Bielen E, Amery A (1991) Heritability of aerobic power and anaerobic energy generation during exercise. J Appl Physiol. 70: 357–362
Bouchard C, An P, Rice T (1999) Familial aggregation of VO2 max response to exercise training: results from the HERITAGE Family Study. J Appl Physiol. 87: 1003–1008
Bouchard C, Simoneau J, Lortie G, Boulay M, Marcotte M, Thibault M (1986) Genetic effects in human skeletal muscle fiber type distribution and enzyme activities. Can J Physiol Pharmacol. 64: 1245–1251
Ahmetov I, Rogozkin V (2009) Genes, athlete status and training – An overview. Med Sport Sci. 54: 43–71
Bouchard C, Leon A, Rao D, Skinner J, Wilmore J, Gagnon J (1995) The HERITAGE family study. Aims, design, and measurement protocol. Med Sci Sports Exerc. 27: 721–729
Rivera MA, Dionne FT, Wolfarth B (1997) Muscle-specific creatine kinase gene polymorphisms in elite endurance athletes and sedentary controls. Med Sci Sports Exerc. 29: 1444–1447
Rankinen T, Wolfarth B, Simoneau JA (2000) No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J Appl Physiol. 88: 1571–1575
Wolfarth B, Rankinen T, S Mühlbauer S et al. (2008) Endothelial nitric oxide synthase gene polymorphism and elite endurance athlete status: the Genathlete study. Scand J Med Sci Sports. 18: 485–490
Defoor J, Martens K, Matthijs G (2005) The caregene study: muscle-specific creatine kinase gene and aerobic power in coronary artery disease. Eur J Cardivasc Pre Rehabil. 12: 415–417
Gene – Exercise Research Study (GERS). http://clinicaltrials.gov/ct2/show/NCT00976742. Accessed October 22, 2010
Nazarov IB, Woods DR, Montgomery HE (2001) The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet. 9: 797–801
Ahmetov II, Mozhayskaya IA, Flavell DM (2006) PPARa gene variation and physical performance in Russian athletes. Eur J Appl Physiol. 97: 103–108
Ahmetov II, Williams AG, Popov DV (2009) The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes. Hum Genet. 126: 751–761
Ash GI, Scott RA, Deason M (2010) No association between ACE gene variation and endurance athlete status in Ethiopians. In Press. Med Sci Sports Exerc
Onywera V, Scott R, Boit M, Pitsiladis Y (2006) Demographic characteristics of elite Kenyan endurance runners. J Sports Sci. 24: 415–422
Scott RA, Georgiades E, Wilson RH (2003) Demographic Characteristics of Elite Ethiopian Endurance Runners. Med Sci Sports Exerc. 35: 1727–1732
Scott RA, Pitsiladis YP (2007) Genotypes and Distance Running: Clues from Africa. Sports Medicine. 37: 1–4
Moran CN, Scott RA, Adams SM (2004) Y Chromosome Haplogroups of Elite Ethiopian Endurance Runners. Hum Genet. 115: 492–497
Scott RA, Wilson RH, Goodwin WH (2005) Mitochondrial DNA Lineages of Elite Ethiopian Athletes. Comp Biochem Physiol B Biochem Mol Biol. 140: 497–503
Scott RA, Moran CN, Wilson RH (2005) No Association Between Angiotensin Converting Enzyme (ACE) Gene Variation and Endurance Athlete Status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol. 141: 169–175
Yang N, MacArthur D, Gulbin J (2003) ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 73: 627–631
Montgomery HE, Marshall R, Hemingway H (1998) Human gene for physical performance. Nature. 393: 221–222
Montgomery HE, Clarkson P, Dollery C (1997) Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 96: 741–747
Cerit M, Colakoglu M, Erdogan M, Berdeli A, Cam F (2006) Relationship between ace genotype and short duration aerobic performance development. Eur J Appl Physiol. 98: 461–465
He Z, Hu Y, Feng L (2006) Polymorphisms in the HBB gene relate to individual cardiorespiratory adaptation in response to endurance training. Br J Sports Med. 40: 998–1002
Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 271: 17771–17778
Jiang C, Lu H, Vincent KA (2002) Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics. 8: 23–32
Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev. 14: 1983–1991
Semenza GL (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 88: 1474–1480
Jiang BH, Semenza GL, Bauer C, Marti HH (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 271: 1172–C1180
Prior SJ, Hagberg JM, Phares DA (2003) Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): association with maximal oxygen consumption. Physiol Genomics. 15: 20–26
Döring F, Onur S, Fischer A (2010) A common haplotype and the Pro582Ser polymorphism of the hypoxia-inducible factor-1alpha (HIF1A) gene in elite endurance athletes. J Appl Physiol. 108: 1497–1500
Sander M, Chavoshan B, Victor RG (1999) A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 33: 937–942
Zatz R, Baylis C (1998) Chronic nitric oxide inhibition model six years on. Hypertension. 32: 958–964
Higashi Y, Sasaki S, Kurisu S (1999) Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 100: 1194–1202
Wang J, Wolin MS, Hintze TH (1993) Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs. Circ Res. 73: 829–838
Marsden PA, Heng HH, Scherer SW (1993) Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 268: 17478–17488
Erbs S, Baither Y, Linke A (2003) Promoter but not exon 7 polymorphism of endothelial nitric oxide synthase affects training-induced correction of endothelial dysfunction. Arterioscler Thromb Vasc Biol. 23: 1814–1819
Data SA, Roltsch MH, Hand B, Ferrell RE, Park JJ, Brown MD (2003) eNOS T-786C genotype, physical activity, and peak forearm blood flow in females. Med Sci Sports Exerc. 35: 1991–1997
Kimura T, Yokoyama T, Matsumura Y (2003) NOS3 genotype-dependent correlation between blood pressure and physical activity. Hypertension. 41: 355–360
Rankinen T, Rice T, Perusse L (2000) NOS3 Glu298Asp genotype and blood pressure response to endurance training: the HERITAGE family study. Hypertension. 36: 885–889
Turner DC, Wallimann T, Eppenberger HM (1972) A Protein That Binds Specifically to the M- ine of Skeletal Muscle Is Identified as the Muscle Form of Creatine Kinase. Proc Nat Acad Sci USA. 70: 702–705
Wallimann T, Schlosser T, Eppenberger HM (1984) Function of M-line-bound Creatine Kinase as Intramyofibrillar ATP regenerator at the receiving end of the Phosphorylcreatine Shuttle in Muscle. J Biol Chem. 259: 5238–5246
Holloszy JO, Coyle EF (1984) Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 56: 831–838
Yamashita K, Yoshioka T (1991) Profiles of creatine kinase isoenzyme compositions in single muscle fibers of different types. J Muscle Res Cell Motil. 12: 37–44
van Deursen J, Heerschap A, Oeriemans F (1993) Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell. 74: 621–631
Rivera MA, Dionne FT, Simoneau JA (1997) Muscle-specific creatine kinase gene polymorphism and VO2max in the HERITAGE Family Study. Med Sci Sports Exerc. 29: 1311–1317
Rivera MA, Pérusse L, Simoneau JA (2006) Linkage between a muscle-specific CK gene marker and VO2max in the HERITAGE Family Study. Med Sci Sports Exerc. 1999;31:698–701
Zhou DQ, Hu Y, Liu G, Gong L, Xi Y, Wen L. Muscle-specific creatine kinase gene polymorphism and running economy responses to an 18-week 5000-m training programme. Br J Sports Med. 40: 988–991
Clarke IJ, Henry BA (2010) Targeting energy expenditure in muscle as a means of combating obesity. Clin Exp Pharmacol Physiol. 37: 121–124
Stump CS, Henriksen EJ, Wei Y, Sowers JR (2006) The metabolic syndrome: role of skeletal muscle metabolism. Ann Med. 38: 389–402
Kelley DE (2005) Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 115: 1699–1702
Kiens B (2006) Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev. 85: 205–243
Schneider AJ, Friedmann T (2006) Gene transfer in sports: an opening scenario for genetic enhancement of normal “human traits” Advances in Genetics. 51: 37–49
Dartmouth scientists genetically engineer muscular mice. http://www.futurepundit.com/archives/003886.html. Accessed November 16, 2006
Keim B (2010) Athletes beware, scientists hot on gene doping trail. http://www.wired.com/wiredscience/2010/02/gene-doping-detection/
Hernandez J, Cooper J, Babel N, Morton C, Rosemurgy AS (2010) TNFalpha gene delivery therapy for solid tumors. Expert Opin Biol Ther. 10: 993–999
López-Lázaro M (2010) A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med. 16: 144–153
Muntoni F, Wells D (2007) Genetic treatments in muscular dystrophies. Curr Opin Neurol. 20: 590–594
Bushby K, Lochmüller H, Lynn S, Straub V (2009) Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet. 374: 1849–1856
Gene therapy for cancer. http://www.medic8.com/cancer/gene-therapy.htm
Kulkarni M (2009) Gene therapy for human severe combined immunodeficiency disease. http://www.buzzle.com/articles/gene-therapy-for-human-severe-combined-immunodeficiency-scid-disease.html
Gene therapy for Parkinson's disease is safe and some patients benefit, according to study. http://www.sciencedaily.com/releases/2007/06/070622101037.htm. Accessed June 25, 2007
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86: 1343–1346
Williams AG, Rayson MP, Jubb M (2000) The ACE gene and muscle performance. Nature. 403: 614
Woods DR, World M, Rayson MP (2002) Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol. 86: 240–244
Zhang B, Tanka H, Shono N (2003) The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet. 63: 139–144
Collins M, Xenophontos SL, Cariolou MA (2004) The ACE gene and endurance performance during the South African Ironman Triathlons Med Sci Sports Exerc. 36: 1314–1320
Eynon N, Ruiz JR, Femia P (2012) The ACTN3 R577X polymorphism across three groups of elite male European athletes. PLoS One. 7(8): e43132
Gayagay G, Yu B, Hambly B (1998) Elite endurance athletes and the ACE I allele- the role of genes in athletic performance. Hum Genet. 103: 48–50
Taylor R, CDS CM, Fallon K, Bockxmeer F (1999) Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol. 87: 1035–1037
Yu N, Chen FC, Ota S (2002) Larger Genetic Differences Within Africans Than Between Africans and Eurasians. Genetics. 161: 269–274
Zhao B, Moochhala SM, Tham S (2003) Relationship between angiotensin-converting enzyme ID polymorphism and VO(2max) of Chinese males. Life Sci. 73: 2625–2630
Hagberg JM, Ferrell RE, McCole SD, Wilund KR, Moore GE (1998) VO2 max is associated with ACE genotype in postmenopausal women. J Appl Physiol. 85: 1842–1846
Scott RA, Irving R, Irwin L (2010) ACTN3 and ACE genotypes in elite Jamaican and US sprinters. Med Sci Sports Exerc. 42: 107–112
Kalson NS, Thompson J, Davies AJ (2009) The effect of angiotensin-converting enzyme genotype on acute mountain sickness and summit success in trekkers attempting the summit of Mt. Kilimanjaro (5,895 m). Eur J Appl Physiol. 105: 373–379
Woods D, Hickman M, Jamshid Y (2001) Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet. 108: 230–232
Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37: 907–925
Auboeuf D, Rieusset J, Fajas L (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- a in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46: 1319–1327
Krey G, Braissant O, L’Horset F (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 11: 779–791
Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature. 405: 421–424
Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA (2003) Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta. 1633: 43–50
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med. 53: 409–435
Wang YX, Zhang CL, Yu RT (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2: e294
Schuler M, Ali F, Chambon C (2006) PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 4: 407–414
Pilegaard H, Richter EA (2008) PGC-1α: important for exercise performance? J Appl Physiol. 104: 1264–1265
Jamshidi Y, Montgomery HE, Hense HW (2002) Peroxisome proliferator–activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 105: 950–955
Uthurralt J, Gordish-Dressman H, Bradbury M (2007) PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet. 8: 55
Russell AP, Feilchenfeldt J, Schreiber S (2003) Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 52: 2874–2881
Kagaya Y, Kanno Y, Takeyama D (1990) Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. Circulation. 81: 1353–1361
Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol. 267: 742–750
Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP (2000) Deactivation of peroxisome proliferator-activated receptor a during cardiac hypertrophic frowth. J Clin Invest. 105: 1723–1730
Wang YX, Lee CH, Tiep S (2003) Peroxisomeproliferator-activated receptor d activates fat metabolism to prevent obesity. Cell. 113: 159–170
Tanaka T, Yamamoto J, Iwasaki S (2003) Activation of peroxisome proliferator-activated receptor d induces fatty acid b-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA. 100: 15924–15929
Dressel U, Allen TL, Pippal JB (2003) The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol;17: 2477–2493
Amri EZ, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA (1995) Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J Biol Chem. 270: 2367–2371
Ahmetov II, Astranenkova IV, Rogozkin VA (2007) Association of PPARD gene polymorphism with human physical performance. Mol Biol (Mosk). 41: 852–857
Auwerx J (1999) PPARgamma, the ultimate thrifty gene. Diabetologia. 42: 1033–1049
Masud S, Ye S, SAS Group (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 40: 773–780
Vänttinen M, Nuutila P, Pihlajamäki J (2005) The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake uepends on obesity: a positron emission tomography study. J Clin Endocrinol Metab. 90: 4249–4254
Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM (2007) Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado. Metabolism. 56: 388–393
North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH (1999) A common nonsense mutation results in alphaactinin-3 deficiency in the general population. Nat Genet. 21: 353–354
Yang N, MacArthur DG, Wolde B (2007) The ACTN3 R577X polymorphism in East and West African athletes. Med Sci Sports Exerc. 39: 1985–1988
Ahmetov II, Druzhevskaya AM, Astratenkova IV, Popov DV, Vinogradova OL, Rogozkin VA (2010) The ACTN3 R577X polymorphism in Russian endurance athletes. Br J Sports Med. 44: 649–652
Niemi AK, Majamaa K (2005) Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. Eur J Hum Genet. 13: 965–969
Papadimitriou ID, Papadopoulos C, Kouvatsi A, Triantaphyllidis C (2008) The ACTN3 gene in elite Greek track and field athletes. Int J Sports Med. 29: 352–355
MacArthur DG, Seto JT, Chan S (2008) An Actn3 knockout mouse provides mechanistic insights into the association between α-actinin-3 deficiency and human athletic performance. Hum Mol Genet. 17: 1076–1086
Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev. 72: 449–489
Eckardt KU (2001) After 15 years of success––perspectives of erythropoietin therapy. Nephrol Dial Transplant. 16: 1745–1749
Gaffney GR, Parisotto R (2007) Gene doping: a review of performance-enhancing genetics. Pediatr Clin North Am. 54: 807–822
Regulier E, Schneider BL, Deglon N, Beuzard Y, Aebischer P (1998) Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther. 5: 1014–1022
Chenuaud P, Larcher T, Rabinowitz JE (2004) Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 103: 3303–3304
Gao G, Lebherz C, Weiner DJ (2004) Erythropoietin gene therapy leads to autoimmune anemia in macaques. ]Blood. 103: 3300–3302
de la Chapelle A, Sistonen P, Lehvaslaiho H, Ikkala E, Juvonen E (1993) Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 341: 82–84
Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 102: 898–901
Walgenbach KJ, Gratas C, Shestak KC, Becker D (1995) Ischaemia-induced expression of bFGF in normal skeletal muscle: a potential paracrine mechanism for mediating angiogenesis in ischaemic skeletal muscle. Nat Med. 1: 453–459
Bray MS (2008) Implications of gene-behavior interactions: prevention and intervention for obesity. Obesity (Silver Spring). 16: S72–S78
Stefan N, Vozarova B, Del Parigi A (2002) The Gln223Arg polymorphism of the leptin receptor in Pima Indians: influence on energy expenditure, physical activity and lipid metabolism. Int J Obes Relat Metab Disord. 26: 1629–1632
Meier U, Gressner AM (2004) Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. Clin Chem. 50: 1511–1525
Pistilli EE, Gordish-Dressman H, Seip RL (2007) Resistin Polymorphisms Are Associated with Muscle, Bone, and Fat Phenotypes in White Men and Women. Obesity (Silver Spring). 15: 392–402
Richert L, Chevalley T, Manen D, Bonjour JP, Rizzoli R, Ferrari S (2007) Substitution in the Leptin Receptor Bone Mass in Prepubertal Boys Is Associated with a Gln223Arg Amino Acid. J Clin Endocrinol Metab. 92: 4380–4386
Frayn KN, Arner P, Yki-Järvinen H (2006) Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem. 42: 89–103
Dyck DJ, Heigenhauser GJ, Bruce CR (2006) The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 186: 5–16
Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor alpha. Am J Physiol Endocrinol Metab. 2004;287:E616–E621
Junkin KA, Dyck DJ, Mullen KL, Chabowski A, Thrush AB (2009) Resistin acutely impairs insulin-stimulated glucose transport in rodent muscle in the presence, but not absence, of palmitate. Am J Physiol Regul Integr Comp Physiol. 296: R944–R951
Yamauchi T, Kamon J, Waki H (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7: 941–946
Singh MK, Krisan AD, Crain AM, Collins DE, Yaspelkis BB, 3rd (2003) High-fat diet and leptin treatment alter skeletal muscle insulin-stimulated phosphatidylinositol 3-kinase activity and glucose transport. Metabolism. 52: 1196–1205
Yaspelkis BB, 3rd, Singh MK, Krisan AD (2004) Chronic leptin treatment enhances insulin-stimulated glucose disposal in skeletal muscle of high-fat fed rodentss. Life Sci. 74: 1801–1816
Dyck DJ (2009) Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab. 34: 396–402
Fischer H, Esbjornsson M, Sabina RL, Stromberg A, Peyrard-Janvid M, Norman B (2007). AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol. 103: 315–322
Norman B, Glenmark B, Jansson E (1995) Muscle AMP deaminase deficiency in 2% of a healthy population. Muscle Nerve. 18: 239–241
Verzijl HT, van Engelen BG, Luyten JA (1998) Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol. 44: 140–143
Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW (1992) Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci. 89: 6457–6461
Sabina RL, Fishbein WN, Pezeshkpour G, Clarke PR, Holmes EW (1992) Molecular analysis of the myoadenylate deaminase deficiencies. Neurology. 42: 170–179
Sabina RL, Swain JL, Olanow CW (1984) Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 73: 720–730
De Ruiter CJ, May AM, van Engelen BG, Wevers RA, Steenbergen-Spanjers GC, de Haan A (2002) Muscle function during repetitive moderateintensity muscle contractions in myoadenylate deaminase-deficient Dutch subjects. Clin Sci (Lond). 102: 531–539
Rico-Sanz J, Rankinen T, Joanisse DR (2003) Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. Physiol Genomics. 14: 161–166
Rubio JC, Martin MA, Rabadan M (2005) Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance? J Appl Physiol. 98: 2108–2112
Lucia A, Martin MA, Esteve-Lanao J (2006) C34T mutation of the AMPD1 gene in an elite white runner. Br J Sports Med. 40: e7
Sinkeler SP, Binkhorst RA, Joosten EM, Wevers RA, Coerwinkei MM, Oei TL (1987) AMP deaminase deficiency: study of the human skeletal muscle purine metabolism during ischaemic isometric exercise. Clin Sci (Colch). 72: 475–482
De Ruiter CJ, Van EBG, Wevers RA, De Haan A (2000) Muscle functionv during fatigue in myoadenylate deaminase-deficient Dutch subjects. Clin Sci (Colch). 98: 579–585
Norman B, Sabina RL, Jansson E (2001) Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol. 91: 258–264
Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW (2001) Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol. 553: 881–889
Pollin TI, Damcott CM, Shen HQ (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 322: 1702–1705
Yoshitomi H, Yamashita K, Abe S, Tanak I (1998) Differential regulation of mouse uncoupling proteins among brown adipose tissue, white adipose tissue, and skeletal muscle in chronic beta 3 adrenergic receptor agonist treatment. Biochem Biophys Res Commun. 253: 85–91
Gleeson M, Blannin AK, Walsh NP, Field CN, Pritchard JC (1998) Effect of exercise-induced muscle damage on the blood lactate response to incremental exercise in humans. Eur J Appl Physiol Occup Physiol. 77: 292–295
Boss O, Hagen T, Lowell BB (2000) Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes. 49: 143–156
Hawley JA, Brouns F, Jeukendrup A (1998) Strategies to enhance fat utilisation during exercise. Sports Med. 25: 241–257
Klaus S, Casteilla L, Bouillaud F, Ricquier D (1991) The uncouplingprotein UCP: a membraneous mitochondrial ion carrier exclusively expressed in brown adipose tissue. Int J Biochem. 23: 791–801
Monemdjou S, Hofmann WE, Kozak LP, Harper ME (2000) Increased mitochondrial proton leak in skeletal muscle mitochondria of UCP1-deficient mice. Am J Physiol Endocrinol Metab. 279: E941–E946
Erlanson-Albertsson C (2003) The role of uncoupling proteins in the regulation of metabolism. Acta Physiol Scand. 178: 405–412
Klaus S, Rudolph B, Dohrmann C, Wehr R (2005) Expression of uncoupling protein 1 in skeletal muscle decreases muscle energy efficiency and affects thermoregulation and substrate oxidation. Physiol Genomics. 21: 193–200
Garruti G, Ricquier D (1992) Analysis of uncoupling protein and its mRNA in adipose tissue deposits of adult humans. Int J Obes Relat Metab Disord. 16: 383–390
Astrup A, Toubro S, Dalgaard LT, Urhammer SA, Sùrensen TIA, Pedersen O (1999) Impact of the v/v 55 polymorphism of the uncoupling protein 2 gene on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord. 23: 1030–1034
Buemann B, Schierning B, Toubro S (2001) The association between the val/ala-55 polymorphism of the uncoupling protein 2 gene and exercise efficiency. Int J Obes Relat Metab Disord. 25: 467–471
Ahmetov II, Hakimullina AM, Shikhova JV, Rogozkin VA (2008) The ability to become an elite endurance athlete depends on the carriage of high number of endurance-related alleles. Eur J Hum Gene. 16: 341
Cagliani R, Fumagalli M, Pozzoli U (2009) Diverse evolutionary histories for beta-adrenoreceptor genes in humans. Am J Hum Genet. 85: 64–75
Kurnik D, Muszkat M, Li C (2006) Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther. 79: 173–185
Chruscinski A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L (2001) Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Mol Pharmacol. 60: 955–962
Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem. 274: 16701–16708
Hoehe MR, Berrettini WH, Lentes KU (1988) Dra I identifies a two allele DNA polymorphism in the human alpha 2-adrenergic receptor gene (ADRAR), using a 5.5 kb probe (p ADRAR). Nucleic Acids Res. 16: 9070
Wolfarth B, Rivera MA, Oppert JM (2000) A polymorphism in the alpha2a-adrenoceptor gene and endurance athlete status. Med Sci Sports Exerc. 32: 1709–1712
Rao DC, Province MA, Leppert MF () A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. Am J Hypertens. 2003;16:148–150
Province MA, Kardia SL, Ranade K (2003) A meta-analysis of genome-wide linkage scans for hypertension: the National Heart, Lung and Blood Institute Family Blood Pressure Program. Am J Hypertens. 16: 144–147
Wilk JB, Myers RH, Pankow JS (2006) Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study. Ann Hum Genet. 70: 566–573
Heinonen P, Koulu M, Pesonen U (1999) Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab. 84: 2429–2433
Ueno LM, Frazzatto ES, Batalha LT (2006) Alpha2B-adrenergic receptor deletion polymorphism and cardiac autonomic nervous system responses to exercise in obese women. Int J Obes (Lond). 30: 214–220
Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 47: 1135–1142
Podlowski S, Wenzel K, Luther HP (2000) Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med. 78: 87–93
Stanton T, Inglis GC, Padmanabhan S, Dominiczak AF, Jardine AG, Connell JM (2002) Variation at the beta-1 adrenoceptor gene locus affects left ventricular mass in renal failure. J Nephrol. 15: 512–518
Sandilands AJ, Parameshwar J, Large S, Brown MJ, O'Shaughnessy KM (2005) Confirmation of a role for the 389R>G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart. 91: 1613–1614
Borjesson M, Magnusson Y, Hjalmarson A, Andersson B (2000) A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 21: 1853–1858
Ranade K, Jorgenson E, Sheu WH (2002) A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet. 70: 935–942
Defoor J, Martens K, Zielinska D (2006) The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease. Eur Heart J. 27: 808–816
Reihsaus E, Innis M, MacIntyre N, Liggett SB (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 8: 334–339
Bruck H, Leineweber K, Beilfuss A (2003) Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation. Clin Pharmacol Ther. 74: 255–263
Meirhaeghe A, Helbecque N, Cottel D, Amouyel P (1999) Beta2-adrenoceptor gene polymorphism, body weight, and physical activity. Lancet. 353: 896
Meirhaeghe A, Helbecque N, Cottel D, Amouyel P (2000) Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat Metab Disord. 24: 382–387
Meirhaeghe A, Luan J, Selberg-Franks P () The effect of the Gly16Arg polymorphism of the beta(2)-adrenergic receptor gene on plasma free fatty acid levels is modulated by physical activity. J Clin Endocrinol Metab. 2001;86:5881–5887
Wolfarth B, Rankinen T, Mühlbauer S (2007) Association between a beta2-adrenergic receptor polymorphism and elite endurance performance. Metabolism. 56: 1649–1651
Giacobino JP (1995) Beta 3-adrenoceptor: an update. Eur J Endocrinol. 132: 377–385
Katzmarzyk PT, Perusse L, Bouchard C (1999) Genetics of abdominal visceral fat levels. Am J Human Biol. 11: 225–235
Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC (1995) Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med. 333: 348–351
Kahara T, Takamura T, Hayakawa T (2002) Prediction of exercise-mediated changes in metabolic markers by gene polymorphism. Diabetes Res Clin Pract.57: 105–110
Allison DB, Heo M, Faith MS, Pietrobelli A (1998) Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. Int J Obes Relat Metab Disord. 22: 559–566
Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T (1998) Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab. 83: 2441–2444
Kurokawa N, Nakai K, Kameo S, Liu ZM, Satoh H (2001) Association of BMI with the beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res. 9: 741–745
Folland JP, Mc Cauley TM, Phypers C, Hanson B, Mastana SS (2012) The relationship of testosterone and AR CAG repeat genotype with knee extensor muscle function of young and older men. Exp. Gerontol. 47(6): 437–43
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag Wien
About this chapter
Cite this chapter
Blume, K., Pitsiladis, Y., Wang, G., Wolfarth, B. (2018). Genetik der Leistungsfähigkeit und Trainierbarkeit. In: Bachl, N., Löllgen, H., Tschan, H., Wackerhage, H., Wessner, B. (eds) Molekulare Sport- und Leistungsphysiologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1591-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1591-6_17
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1590-9
Online ISBN: 978-3-7091-1591-6
eBook Packages: Medicine (German Language)